Payment overview · 2025
General Payments
$39.56
2 reported records · 2 companies
Healthcare provider profile · identity verified
Karthik Nune, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CHICAGO, IL · NPI 1376993626
Verified facts
What the public records show
CMS Open Payments records show Karthik Nune, M.D. received $39.56 in general payments during 2025 across 2 reported records.
ABBVIE INC. accounted for 53.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.16 | 53.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.40 | 46.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $39.56 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 540 | 164 |
| Gabapentin | Gabapentin | 466 | 102 |
| Omeprazole | Omeprazole | 270 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 245 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 242 | 71 |
| Losartan Potassium | Losartan Potassium | 237 | 53 |
| Lisinopril | Lisinopril | 210 | 65 |
| Furosemide | Furosemide | 197 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 179 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 172 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 43 |
| Alendronate Sodium | Alendronate Sodium | 156 | 37 |
| Trazodone Hcl | Trazodone Hcl | 154 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 139 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 31 |
| Montelukast Sodium | Montelukast Sodium | 135 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 52 |
| Prednisone | Prednisone | 132 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 33 |
| Allopurinol | Allopurinol | 116 | 32 |
| Eliquis | Apixaban | 110 | 25 |
| Warfarin Sodium | Warfarin Sodium | 104 | 21 |
| Glipizide | Glipizide | 103 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 29 |
| Sertraline Hcl | Sertraline Hcl | 100 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 31 |
| Jardiance | Empagliflozin | 97 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 96 | 27 |
| Metformin Hcl Er | Metformin Hcl | 94 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 25 |
| Famotidine | Famotidine | 83 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 23 |
| Potassium Chloride | Potassium Chloride | 82 | 26 |
| Buspirone Hcl | Buspirone Hcl | 76 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 73 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 18 |
| Metformin Hcl | Metformin Hcl | 68 | 24 |
| Clonazepam | Clonazepam | 66 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 22 |
| Lorazepam | Lorazepam | 66 | suppressed |
| Alprazolam | Alprazolam | 65 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 17 |
| Simvastatin | Simvastatin | 65 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 25 |
| Carvedilol | Carvedilol | 62 | 19 |
| Meloxicam | Meloxicam | 60 | 14 |
| Clonidine Hcl | Clonidine Hcl | 58 | 12 |
| Atenolol | Atenolol | 57 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 41 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 28 |
| Celecoxib | Celecoxib | 48 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | 12 |
| Hydrocortisone | Hydrocortisone | 48 | 25 |
| Spironolactone | Spironolactone | 47 | 17 |
| Ezetimibe | Ezetimibe | 46 | 14 |
| Finasteride | Finasteride | 45 | 12 |
| Fluconazole | Fluconazole | 45 | 33 |
| Baclofen | Baclofen | 43 | suppressed |
| Trulicity | Dulaglutide | 43 | suppressed |
| Klor-Con M20 | Potassium Chloride | 42 | 20 |
| Ozempic | Semaglutide | 42 | suppressed |
| Topiramate | Topiramate | 42 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | 12 |
| Lovastatin | Lovastatin | 40 | 11 |
| Glipizide Er | Glipizide | 39 | 12 |
| Azithromycin | Azithromycin | 38 | 27 |
| Bupropion Xl | Bupropion Hcl | 38 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 12 |
| Diazepam | Diazepam | 36 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 35 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Mirtazapine | Mirtazapine | 33 | 12 |
| Meclizine Hcl | Meclizine Hcl | 31 | 15 |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Minoxidil | Minoxidil | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 12 |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 17 | suppressed |
| Cholestyramine Light | Cholestyramine | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Repaglinide | Repaglinide | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Victoza 2-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $39.56 · 2 records | ABBVIE INC. | UBRELVY, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error